Cancer incidence among Parkinson's disease patients in a 10-yrs time-window around disease onset: A large-scale cohort study

Parkinsonism and Related Disorders

Volumn 28, Issue , 2016, Pages 68-72

  Peretz, Chava ^a   Gurel, Ron ^a   Rozani, Violet ^a   Gurevich, Tanya ^b   El Ad, Baruch ^c   Tsamir, Judith ^c   Giladi, Nir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

Cancer; Cohort study; Comorbidity; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT;

AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CENTRAL NERVOUS SYSTEM TUMOR; COHORT ANALYSIS; COLON CANCER; FEMALE; HUMAN; ISRAELI; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CANCER; PANCREAS CANCER; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; RETROSPECTIVE STUDY; STANDARDIZED INCIDENCE RATIO; THYROID CANCER; COMORBIDITY; INCIDENCE; ISRAEL; MIDDLE AGED; NEOPLASM; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; ISRAEL; MALE; MIDDLE AGED; NEOPLASMS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; RISK;

EID: 84974807814     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.04.028     Document Type: Article

References (28)

1. Chillag-Talmor O., Giladi N., Linn S., Gurevich T., El-Ad B., Silverman B., et al. Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large israeli population. J. Parkinsons Dis. 2011, 1:35-47. 10.3233/JPD-2011-11024.
2. Thaler A., Ash E., Gan-Or Z., Orr-Urtreger A., Giladi N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J. Neural Transm. 2009, 116:1473-1482. 10.1007/s00702-009-0303-0.
3. Bajaj A., Driver J.A., Schernhammer E.S. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010, 21:697-707. 10.1007/s10552-009-9497-6.
4. Ong E.L.H., Goldacre R., Goldacre M. Differential risks of cancer types in people with Parkinson's disease: a national record-linkage study. Eur. J. Cancer 2014, 50:2456-2462. 10.1016/j.ejca.2014.06.018.
5. Catalá-López F., Suárez-Pinilla M., Suárez-Pinilla P., Valderas J.M., Gómez-Beneyto M., Martinez S., et al. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother. Psychosom. 2014, 83:89-105. 10.1159/000356498.
6. Wirdefeldt K., Weibull C.E., Chen H., Kamel F., Lundholm C., Fang F., et al. Parkinson's disease and cancer: a register-based family study. Am. J. Epidemiol. 2014, 179:85-94. 10.1093/aje/kwt232.
7. Staropoli J.F. Tumorigenesis and neurodegeneration: two sides of the same coin?. Bioessays 2008, 30:719-727. 10.1002/bies.20784.
8. Schernhammer E., Chen H., Ritz B. Circulating melatonin levels: possible link between Parkinson's disease and cancer risk?. Cancer Causes Control 2006, 17:577-582. 10.1007/s10552-005-9002-9.
9. Inzelberg R., Rabey J.M., Melamed E., Djaldetti R., Reches A., Badarny S., et al. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. J. Neural Transm. 2011, 118:1199-1207. 10.1007/s00702-011-0580-2.
10. Lin P.-Y., Chang S.-N., Hsiao T.-H., Huang B.-T., Lin C.-H., Yang P.-C. Association between Parkinson disease and risk of cancer in Taiwan. JAMA Oncol. 2015, 1-8. 10.1001/jamaoncol.2015.1752.
11. Rugbjerg K., Friis S., Lassen C.F., Ritz B., Olsen J.H. Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. Int. J. Cancer 2012, 131:1904-1911. 10.1002/ijc.27443.
12. Liu R., Gao X., Lu Y., Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011, 76:2002-2009. 10.1212/WNL.0b013e31821e554e.
13. A. Lifshitz, S. Fischler, Chairman. Dictiar, to. Keenan Bock, Cancer Incidence and Mortality in Israel, 1990-2010 (Hebrew), (2013) 1-9. (accessed 09.08.15). http://www.health.gov.il/PublicationsFiles/Trends_cancer1990-2010.pdf.
14. Inzelberg R., Cohen O.S., Aharon-Peretz J., Schlesinger I., Gershoni-Baruch R., Djaldetti R., et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 2012, 78:781-786. 10.1212/WNL.0b013e318249f673.
15. Agalliu I., San Luciano M., Mirelman A., Giladi N., Waro B., Aasly J., et al. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease. JAMA Neurol. 2015, 72:58. 10.1001/jamaneurol.2014.1973.
16. Hernán M.A., Takkouche B., Caamaño-Isorna F., Gestal-Otero J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 2002, 52:276-284. 10.1002/ana.10277.
17. Quik M., Perez X.A., Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov. Disord. 2012, 27:947-957. 10.1002/mds.25028.
18. Ishihara L.S., Brayne C. What is the evidence for a premorbid Parkinsonian personality: a systematic review. Mov. Disord. 2006, 21:1066-1072. 10.1002/mds.20980.
19. Brenner S.R., Chen H., Kamel F., Park Y., Hollenbeck A. Smoking duration, intensity, and risk of Parkinson diseases. Neurology 2010, 75:2009-2011.
20. Richardson J.R., Shalat S.L., Buckley B., Winnik B., O'Suilleabhain P., Diaz-Arrastia R., et al. Elevated serum pesticide levels and risk of Parkinson disease. Arch. Neurol. 2009, 66:870-875. 10.1001/archneurol.2009.89.
21. Gandini S., Botteri E., Iodice S., Boniol M., Lowenfels A.B., Maisonneuve P., et al. Tobacco smoking and cancer: a meta-analysis. Int. J. Cancer 2008, 122:155-164. 10.1002/ijc.23033.
22. Kim J., Sung H. Gastrointestinal autonomic dysfunction in patients with Parkinson 's disease. J. Mov. Disord. 2015, 8:76-82.
23. Adams-Carr K.L., Bestwick J.P., Shribman S., Lees A., Schrag A., Noyce A.J. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2015, jnnp-2015-311680. 10.1136/jnnp-2015-311680.
24. Guérin A., Mody R., Fok B., Lasch K.L., Zhou Z., Wu E.Q., et al. Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. Aliment. Pharmacol. Ther. 2014, 40:83-92. 10.1111/apt.12789.
25. Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D., Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 2002, 249(Suppl. III):1-5. 10.1007/s00415-002-1301-4.
26. Cersosimo M.G. Gastrointestinal biopsies for the diagnosis of alpha-synuclein pathology in Parkinson's disease. Gastroenterol. Res. Pract. 2015, 2015:1-6. 10.1155/2015/476041.
27. Keshavarzian A., Green S.J., Engen P.A., Voigt R.M., Naqib A., Forsyth C.B., et al. Colonic bacterial composition in Parkinson's disease. Mov. Disord. 2015, 30. n/a-n/a. 10.1002/mds.26307.
28. Louis P., Hold G.L., Flint H.J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 2014, 10.1038/nrmicro3344.